Genetic research on lean mass
The researchers conducted meta-analyses of genome-wide association studies. They looked for genetic variations associated with lean mass in the arms, legs, trunk and whole body, measured using dual-energy X-ray absorptiometry, or DXA.
They report 63 genetic regions associated with these measurements. Among them is a rare variant of the MSTN gene, called p.Ile225Thr, or rs143242500. For leg lean mass, the estimated association is 0.28 standard deviations, with a 95% confidence interval ranging from 0.19 to 0.37.
This unit describes a statistical difference, not a number of kilograms of muscle. The abstract provided specifies neither the total sample size nor the detailed characteristics of the populations studied.
Why researchers are interested in myostatin
The MSTN gene encodes myostatin, a protein that limits the development of skeletal muscle mass. This makes it a therapeutic target for conditions involving muscle loss.
The value of this work lies in providing genetic evidence directly in humans. The authors also state that they characterized the functional consequences of the variant. However, the abstract consulted does not detail these experiments, so it does not allow a precise description of their mechanism or implications.
Biological support, not a validated treatment
DXA measures lean mass, used here to estimate muscle mass. It does not directly measure strength or physical performance. The abstract reports no improvement in these functional outcomes.
Another crucial distinction: carrying a genetic variant is not the same as receiving a drug that inhibits myostatin. This study therefore demonstrates neither the efficacy nor the safety of such a treatment, particularly for preserving muscle during weight loss.
The finding may guide research on this target. On its own, it does not justify changing your training or buying a product marketed as a myostatin inhibitor.
Limitations to keep in mind
Only the PubMed abstract was consulted, not the full text. The sample size, duration, participant characteristics and details of the functional experiments are not specified in the excerpt. Funding and conflicts of interest were not checked.
What we can take away
This MSTN variant strengthens scientific interest in myostatin as a muscle-related target. It does not demonstrate that a treatment would produce greater strength or a clinical benefit.
Sources and provenance
- Genome-wide association study identifies a functional myostatin variant increasing lean mass in humans.
Source date: 2026-11-20.
Journal Article, Meta-Analysis · Résumé PubMed uniquement, texte intégral non consulté


